---
source_pdf: "https://drive.google.com/file/d/1RfZEjBApxlobeiB5myKRWItQFkoHmY-f/view"
drive_folder: "Research"
type: research

ingested: 2025-12-27
original_filename: "Cura Fi Seed Extension.pdf"
---

> **Original:** [View Original PDF](https://drive.google.com/file/d/1RfZEjBApxlobeiB5myKRWItQFkoHmY-f/view)

## Slide 1: CuraFi Seed Extension Raise 2024

CuraFi
$1.5M Seed Extension Raise
2024

Proprietary & Confidential

## Slide 2: Team with Specialty Pharmacy and Managed Care Expertise

**Andrew Ninh**
CEO & Co-Founder
Thiel Fellow. YC Founder. Co-Founder Docbot (acq'd).

**Vish Banthia MD**
CMO & Co-Founder
Digital Health founder, Stanford-trained surgeon

**Jeff Myers**
Head of Payor Partnerships
CEO at Medicaid Health Plans of America

**Tyler Dao**
CTO & Co-Founder
YC Founder. Co-Founder Docbot (acq'd).

**Brian Stiver**
Chief Business Officer
VP at Option Care, Infusion & Specialty Pharmacy operator

**Jodi Harrington NP**
VP, Clinical Services
Director of Nursing at AleraCare, Oncology RN

**Rick Gannotta**
Advisor
Prev. CEO, UCI Health, NYU Health Law & Strategy

**Joel Brill MD**
Advisor
Payor and Risk-bearing Medical Group Expert

**Jayson Slotnik JD**
Advisor
Medicare and Medicaid coverage expert

CuraFi
Proprietary & Confidential
2

## Slide 3: Infusion therapy is an emerging class of next-generation medications.

| | 1.0 Today's drugs | 2.0 Infusion therapy |
| :---------------- | :------------------ | :------------------- |
| **Cost**          | $0 to $200 per dose | $10,000+ per dose    |
| **Form**          | Pill, cream, injection, inhaler | IV                   |
| **Administered by** | Self                | Provider             |
| **Delivery time** | Under 5 seconds     | 30 to 120+ minutes   |
| **Location**      | At Home             | In Office            |
| **Diseases**      | Low to Medium Complexity | High Complexity      |

CuraFi
Proprietary & Confidential
3

## Slide 4: Access is limited due to the high-cost burden on today's system.

Building Blocks of Drug Care

**Payors**
Health plans & Employers
Won't pay for infusions if drugs are not approved and care cost is not managed.

**Drug 1.0 System**
X Changing authorization rules
X Slow payments, no financing
X No care oversight & tracking

**Providers**
Independent Physicians
Won't deliver infusions if inventory is too expensive and reimbursement is uncertain.

CuraFi
Proprietary & Confidential
4

## Slide 5: Demand for infusion drugs will double over the next 5 years.

**$10 Billion US Market**

30M patients in Traditional Medicare
+120M patients in MA and Medicaid
$3-million-MSRP drugs on the way

**Infusion Drug Demand Growth**

*   **CAGR:** 7.6%
*   **Trend:** Significant year-over-year growth in demand from 2018 to 2026, visually doubling over the next 5 years from 2021-2026.
    *   2018: Base level
    *   2020: Increased
    *   2022: Further increased
    *   2024: Significantly increased
    *   2026: Substantially higher than 2024

CuraFi
Proprietary & Confidential
5

## Slide 6: CuraFi Helps Risk-Bearing Orgs and Specialists Monetize Specialty Meds

**Risk-Bearing Org**
Pay for infusions with visibility into care that's cost-controlled.

**CuraFi Drug Risk Manager**
*   Automated formulary
*   VBC alignment with providers
*   Centralized drug procurement

**Network**
Deliver infusions while making more money, more reliably, without the risk.

Patients get access to the life-saving treatments that they need.

CuraFi
Proprietary & Confidential
6

## Slide 7: Network Management Software

*   ACOs/Payors optimize referral networks
*   Monitor prescribing patterns in real-time
*   Understand local incentives (i.e. health system referrals)

**Search Location**
93726
15 miles â–¾
Search

**Specialty**
Ophthalmology
Add specialty

**Filter**
Demographic Heat Map
Infusion Provider
Specialty Pharmacies

---
**Animesh Petkar, MD**
*   Cost per beneficiary: $143.11
*   Total beneficiaries: 274
*   Affiliations: David B Kaye Md Inc

**Value**
High Value: Provider has a low cost per beneficiary.
$124.81 (highlighted on a scale from $150 to $500)

**Quality** â˜…â˜…â˜…â˜…â˜†
Good Quality: Provider has good satisfaction ratings.
75 (on a scale from 0 to 100)

**Commonly Prescribed Drugs**
Avastin
---
**David Kaye, MD**
*   Cost per beneficiary: $301.91
*   Total beneficiaries: 456
*   Affiliations: David B Kaye Md Inc
---
**Robert Graham, MD**

CuraFi
Proprietary & Confidential
7

## Slide 8: Drug Spend / Total Cost of Care Dashboard

*   Automated FDA pipeline, approvals, pricing, etc.
*   Compare to national and local benchmarks
*   Identify non-compliant specialists

**Test ACO**

**Monthly Snapshot**
*   Spend: $983,282
*   Spend increase: 4%
*   Savings: $54,603

**Weekly Spend**
*   $203,282
*   4% above avg

**Membership Growth**
*   New members this week: 135
*   Total members: 45,039

---

**Weekly Top J Code Utilization**

| Rank | Drug   | HCPCS  | Total Spend | % Spend |
| :--- | :----- | :----- | :---------- | :------ |
| 1    | Eylea  | J0178  | $68,384     | 6%      |
| 2    | Prolia | J0897  | $34,827     | 3%      |
| 3    | Cimzia | J0717  | $18,390     | 2%      |

**Weekly J Code Top Movers**

| Rank | Drug     | HCPCS  | Total Spend | Change |
| :--- | :------- | :----- | :---------- | :----- |
| 1    | Xolair   | J2357  | $33,498     | +11%   |
| 2    | Cimzia   | J0717  | $26,393     | +7%    |
| 3    | Gammaked | J1561  | $21,349     | +5%    |

---

**Coverage Areas**
Total Spend: $983,282
(Map of United States with highlighted regions)

**Non-compliant Geographies**

| State | ZIP Code | # Lives | Policy Violations | Est. Loss |
| :---- | :------- | :------ | :---------------- | :-------- |
| FL    | 84723    | 1,409   | 87                | $94,837   |
| CA    | 95736    | 2,039   | 76                | $78,093   |
| TX    | 17468    | 4,598   | 65                | $64,493   |
| OH    | 84626    | 1,322   | 34                | $38,548   |
| NY    | 59438    | 3,345   | 30                | $37,438   |

**Utilization Initiatives**

| Action Item             | Progress | Instances | Savings   |
| :---------------------- | :------- | :-------- | :-------- |
| Part B to Part D        | 22%      | 76        | $75,439   |
| Biosimilar utilization  | 9%       | 56        | $12,390   |
| Infusions done outpatient | 12%      | 24        | $24,298   |

CuraFi
Proprietary & Confidential
8

## Slide 9: Pipeline of 3M Beneficiaries

**Pipeline**
*   Oncology Care Partnersâ„¢
*   ENNOBLE CARE
*   ALL UNITED MEDICAL GROUP
*   HEALTH EXCEL A Physician Alliance
*   ORANGE COUNTY PACE BY INNOVATIVE INTEGRATED HEALTH
*   WellBe SENIOR MEDICAL
*   greater good health
*   Oak St. Health
*   CHOICE CHOICE MEDICAL GROUP PHYSICIANS NETWORK
*   Bespoke HC
*   Vytalize
*   Primary Care ASSOCIATES OF CALIFORNIA Medical Group
*   honest
*   Akira Health
*   Rise HEALTH
*   Harbor Health
*   homeward.
*   astiva HEALTH

**Qualified**
*   MemorialCare Medical Group
*   GREATER NEWPORT PHYSICIANS
*   MYCARE MEDICAL
*   healthly
*   AKIDO

**Scoping Solution**
*   UpStream
*   TPMG YOUR HEALTH, SKILLFULLY GUIDED
*   Community Care OF NORTH CAROLINA
*   pearl
*   CommunityMD

**$3.3B Drug Spend Funnel**

CuraFi
Proprietary & Confidential
9

## Slide 10: Providing value to all stakeholders delivering infusion therapy.

|                       | CuraFi | Synergie Medication Collective | MagellanRx MANAGEMENT | ETS   | Intrafusion By McKesson |
| :-------------------- | :----- | :----------------------------- | :-------------------- | :---- | :---------------------- |
| Takes Risk            | ðŸŸ¢     | âšª                             | âšª                    | âšª    | âšª                      |
| Focus on Medicare/Medicaid | ðŸŸ¢     | âšª                             | âšª                    | âšª    | âšª                      |
| VBC-Aligned Physician Network | ðŸŸ¢     | âšª                             | âšª                    | âšª    | âšª                      |
| Care Team focused on High Cost Drugs | ðŸŸ¢     | âšª                             | âšª                    | âšª    | âšª                      |
| Centralized Drug Procurement (GPO) | ðŸŸ¢     | âšª                             | âšª                    | âšª    | âšª                      |
| Track Total Cost of Care and Outcomes | ðŸŸ¢     | âšª                             | âšª                    | âšª    | âšª                      |

ðŸŸ¢: Solid Green Circle (Implies strong focus/capability)
âšª: Grey Circle (Implies less focus/capability)

CuraFi
Proprietary & Confidential
10

## Slide 11: Insider-led Round to Execute with Customers and get to Series A

**$7.5m Raised to date**

**Investors:**
*   MAX VENTURES
*   AV8 VENTURES
*   1517
*   LOOKING GLASS CAPITAL
*   GSR Ventures /
*   SixThirty
*   Hike Ventures

**Progress:**
*   Design Partner ACOs identified âœ…
*   $5m ARR Pipeline developed âœ…
*   GPO Partnership âœ…

---

**$1.5m Seed Extension**

**Goals for the raise:**
*   $1m in Total Contract Value signed âœ…
*   Savings case study and customer reference âœ…
*   Close 3 ACO customers, expand pipeline to $10m ARR âœ…

CuraFi
Proprietary & Confidential
11

## Slide 12: Let's expand access to life-saving treatments, together.

**Andrew Ninh**
Co-Founder & CEO
andrew@curafi.com

**Keywords:**
Infusion therapy
Orphan drugs
Reinsurance
Personalized formularies